Upgrade to SI Premium - Free Trial

Recent Alzheimer's disease dynamics are a positive for Biogen's Leqembi - analyst

March 11, 2024 2:01 PM
On Monday, Oppenheimer reiterated its Outperform rating and $290 price target for Biogen (NASDAQ: BIIB) amid recent developments in the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Hot List

Next Articles